Interview with Howard Balloch, President, The Balloch Group
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
Address: Canaccord Genuity Asia
Suite C700, 50 Liangmaqiao Rd.
Beijing 100125
China
Tel: 8610-8451-5559
Web: http://www.加通贝祥.com/en/Pages/default.aspx
The Balloch Group (‘TBG’) was established in 2001 by Howard Balloch (Canada’s ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008.
TBG’s professionals are located in Beijing, New York, Shanghai, Hong Kong, Wuhan and Hangzhou serving and investing alongside clients in mergers and acquisitions, capital markets and direct investment transactions.
Advisory Services, Direct Investment
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
Since this interview, Michael Ryde has left Lundbeck China and is now working as Commercial Counsellor, Teamleader Health, at the Danish Embassy in Beijing. Oscar Parra currently holds the position…
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
You began your career at Pfizer, working your way up the organizational ladder, when suddenly you decided to come to China back in 2001, well before China was on the…
This interview was conducted with Christopher Stephens, managing partner of Orrick, Herrington & Sutcliffe’s Asia offices with supporting responses from Xiang Wang, lead partner of the firm’s IP pracitce as…
Could you please give us a brief introduction on CMBA? First and most obviously for new arrivals to our office, since 2011 we have changed locations, making it more convenient…
Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you…
In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re…
What was the transition like from academia into entrepreneurship and what challenges did you face in beginning this company? I realized during this period in the late 1980s that there…
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps…
Could you please give a brief introduction to the ABO and its history? ABO was established in 2005. The CRO business emerged in 2000 in China, and provided services for…
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company Xian-Janssen and then in the China National Pharmaceutical Group. Could you highlight the…
See our Cookie Privacy Policy Here
